Mumbai: Drugmaker Lupin Ltd said on Tuesday that it has settled all patent litigations relating to its US launch of a copy version memantine tablets patented by multinational Forest Laboratories Inc. It did not disclose the settlement amount. Forest sells the drug, used to treat Alzheimer’s Syndrome, under the brand name Namenda. Lupin’s generic version has been approved by the US Food and Drug Administration under Para 4 provision. As per the terms of the settlement, Lupin will be licensed to commercially launch its version in January 2015, or even earlier under special circumstances. Lupin did not disclose the details of such circumstances. Forest’s Namenda tablets generated sales of $949 million in 2008, and accounted for 26% of the company’s net revenue last year.